NASDAQ : ALLR
Allarity Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.8704 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.31M |
| Enterprise Value | 19.62M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 15.91M |
| Shares Outstanding | 15.91M |
| Shares Change (YoY) | +92.11% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 8.05% |
| Float | 15.81M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.14 |
| Forward PS | n/a |
| PB Ratio | 3.92 |
| P/TBV Ratio | 3.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 55.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.11 |
| Quick Ratio | 0.64 |
| Debt / Equity | 6.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.15 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -157.09% |
| Return on Assets (ROA) | -25.31% |
| Return on Invested Capital (ROIC) | -34.28% |
| Return on Capital Employed (ROCE) | -305.29% |
| Weighted Average Cost of Capital (WACC) | 5.16% |
| Revenue Per Employee | $43,125 |
| Profits Per Employee | -$1.54M |
| Employee Count | 8 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -38.70% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 39.01 |
| Average Volume (20 Days) | 130,059 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 168,026 |
| Short Previous Month | 119,190 |
| Short % of Shares Out | 1.06% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 1.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 345,000 |
| Gross Profit | 345,000 |
| Operating Income | -10.80M |
| Pretax Income | -12.33M |
| Net Income | -12.33M |
| EBITDA | -10.80M |
| EBIT | -10.80M |
| Loss Per Share | -$0.79 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 16.98M |
| Total Debt | 22.29M |
| Net Cash | -5.30M |
| Net Cash Per Share | -$0.33 |
| Equity (Book Value) | 3.54M |
| Book Value Per Share | 0.22 |
| Working Capital | 3.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -13.71M |
| Capital Expenditures | -72,000 |
| Depreciation & Amortization | -6,000 |
| Net Borrowing | 20.00M |
| Free Cash Flow | -13.78M |
| FCF Per Share | -$0.87 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -3,128.99% |
| Pretax Margin | -3,575.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -92.11% |
| Shareholder Yield | -92.11% |
| Earnings Yield | -87.49% |
| FCF Yield | -99.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 11, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.52 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |